{"doi":"10.1111/liv.15296","title":"Attribution of diabetes to the development of severe liver disease in the general population","abstract":"BACKGROUND AND AIMS: Diabetes is associated with advanced liver disease and predicts mortality regardless of the primary aetiology of the liver disease. Even a family history of diabetes has been linked to advanced liver fibrosis in non-alcoholic fatty liver disease (NAFLD). However, the fraction of liver-related outcomes in the general population that are attributable to diabetes remains unclear. METHODS: The population attributable fraction (PAF) of diabetes for liver disease as a time-dependent exposure was estimated in the Finnish FINRISK study (n = 28 787) and the British Whitehall II study (n = 7855). We also assessed the predictive ability of a family history of diabetes for liver-related outcomes. Incident diabetes data were from drug purchase/reimbursement and healthcare registries (FINRISK) or follow-up examinations (Whitehall II). Incident severe liver outcomes were identified through linkage with national healthcare registries. RESULTS: Diabetes was associated with a two-fold risk of liver-related outcomes in both the FINRISK (HR, 1.92; p < .001) and Whitehall II (HR, 2.37; p < .001) cohorts, and this remained significant after adjusting for multiple confounders. PAF analyses demonstrated that diabetes explained 12-14% of the risk for severe liver-related outcomes after 10 and 20 years of follow-up. Also, maternal diabetes increased the risk of liver-related outcomes in the FINRISK (HR, 1.43; p = .044) and Whitehall II (HR, 2.04; p = .051) cohorts. CONCLUSION: Approximately 12%-14% of severe liver-related outcomes are attributable to diabetes at the population level. The association between maternal diabetes and liver disease might suggest a mitochondrial genetic mechanism.","journal":"Liver International","year":2022,"id":292528,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9094,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":294813,"name":"Ville Männistö","orcid":"0000-0002-0735-400X","position":1,"is_corresponding":false},{"id":1112,"name":"Veikko Salomaa","orcid":"0000-0001-7563-5324","position":2,"is_corresponding":false},{"id":289750,"name":"Annie Britton","orcid":"0000-0002-6412-5430","position":3,"is_corresponding":false},{"id":856182,"name":"Antti Jula","orcid":"0000-0002-3522-5301","position":4,"is_corresponding":false},{"id":21911,"name":"Satu Männistö","orcid":"0000-0002-8668-3046","position":5,"is_corresponding":false},{"id":856181,"name":"Annamari Lundqvist","orcid":"0000-0002-0262-8585","position":6,"is_corresponding":false},{"id":21973,"name":"Markus Perola","orcid":"0000-0003-4842-1667","position":7,"is_corresponding":false},{"id":94718,"name":"Fredrik Åberg","orcid":"0000-0002-3833-0705","position":8,"is_corresponding":false},{"id":976622,"name":"Miika Vuorinen","orcid":"0000-0002-0399-4931","position":0,"is_corresponding":true}],"reference_count":36,"raw_metadata":null,"created_at":"2026-07-19T00:30:46.209549Z","pmid":"35574998","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}